文献速递白血病淋巴瘤

MAPK-ERK通路驱动T-ALL激素耐药

MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance.
PubMed 文献 · Leukemia · 2021-05-18

儿童T-ALL中IL7R信号激活MAPK-ERK,通过磷酸化BIM使其不能结合BCL2/BCLXL/MCL1而促存活、致激素耐药。MEK抑制剂selumetinib可去磷酸化BIM并在依赖与非依赖IL7的激素耐药PDX中与激素协同;ruxolitinib仅在IL7依赖样本中协同。

要点

  • IL7R通路突变与生理信号激活MAPK-ERK,磷酸化BIM导致激素耐药。
  • MEK抑制剂恢复BIM与抗凋亡蛋白结合,在IL7依赖与非依赖PDX中与激素协同。
  • ruxolitinib仅在IL7依赖激素耐药PDX中与激素协同,应用范围窄于MEK抑制剂。

核心结论

  • MAPK-ERK是儿童T-ALL激素耐药的中心通路,MEK抑制剂较ruxolitinib有更广的再敏化应用。

研究设计与样本

  • 基于儿童T-ALL的PDX样本开展机制与药物协同研究,比较MEK抑制剂与ruxolitinib联合激素的效果。

主要发现

  • 激活型IL7R通路突变与生理IL7R信号均激活MAPK-ERK,通过磷酸化BIM引发激素耐药。
  • 质谱显示磷酸化BIM与BCL2、BCLXL和MCL1结合受损,凋亡平衡偏向存活。
  • MEK抑制剂消除BIM失活磷酸化并恢复其与抗凋亡BCL2家族成员结合。
  • selumetinib在IL7依赖与非依赖的激素耐药儿童T-ALL PDX中均与激素协同。
  • ruxolitinib仅在IL7依赖激素耐药PDX中与激素协同,在IL7非依赖样本中不协同。

临床怎么用

  • 激素耐药T-ALL可考虑MEK抑制剂联合激素以再敏化,尤其不受IL7依赖状态限制。
  • ruxolitinib联合激素的适用人群应限于IL7依赖的激素耐药T-ALL。
  • 研究支持T-ALL患者入组SeluDex试验(NCT03705507)并优化分层治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

(Patho-)physiological activation of the IL7-receptor (IL7R) signaling contributes to steroid resistance in pediatric T-cell acute lymphoblastic leukemia (T-ALL). Here, we show that activating IL7R pathway mutations and physiological IL7R signaling activate MAPK-ERK signaling, which provokes steroid resistance by phosphorylation of BIM. By mass spectrometry, we demonstrate that phosphorylated BIM is impaired in binding to BCL2, BCLXL and MCL1, shifting the apoptotic balance toward survival. Treatment with MEK inhibitors abolishes this inactivating phosphorylation of BIM and restores its interaction with anti-apoptotic BCL2-protein family members. Importantly, the MEK inhibitor selumetinib synergizes with steroids in both IL7-dependent and IL7-independent steroid resistant pediatric T-ALL PDX samples. Despite the anti-MAPK-ERK activity of ruxolitinib in IL7-induced signaling and JAK1 mutant cells, ruxolitinib only synergizes with steroid treatment in IL7-dependent steroid resistant PDX samples but not in IL7-independent steroid resistant PDX samples. Our study highlights the central role for MAPK-ERK signaling in steroid resistance in T-ALL patients, and demonstrates the broader application of MEK inhibitors over ruxolitinib to resensitize steroid-resistant T-ALL cells. These findings strongly support the enrollment of T-ALL patients in the current phase I/II SeluDex trial (NCT03705507) and contributes to the optimization and stratification of newly designed T-ALL treatment regimens.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. van der Zwet JCG, Buijs-Gladdines JGCAM, Cordo' V, et al. MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance. Leukemia. 2021. PMID: 34007050. doi:10.1038/s41375-021-01291-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。